Literature DB >> 29019742

The Impact of Hypoxia on Out-of-Field Cell Survival after Exposure to Modulated Radiation Fields.

Hannah F Thompson1, Karl T Butterworth1, Stephen J McMahon1, Mihaela Ghita1, Alan R Hounsell2, Kevin M Prise1.   

Abstract

Advanced radiotherapy techniques such as intensity modulated radiation therapy achieve highly conformal dose distributions within target tumor volumes through the sequential delivery of multiple spatially and temporally modulated radiation fields and have been shown to influence radiobiological response. The goals of this study were to determine the effect of hypoxia on the cell survival responses of different cell models (H460, DU145, A549, MDA231 and FADU) to modulated fields and to characterize the time dependency of signaling under oxic conditions, following reoxygenation and after prolonged hypoxia. Hypoxia was induced by incubating cells at 95% nitrogen and 5% carbon dioxide for 4 h prior to irradiation. The out-of-field response in MDA231 cells was oxygen dependent and therefore selected for co-culture studies to determine the signaling kinetics at different time intervals after irradiation under oxic and hypoxic conditions. Under both oxic and hypoxic conditions, significant increases in cell survival were observed in-field with significant decreases in survival observed out-of-field (P < 0.05), which were dependent on intercellular communication. The in-field response of MDA231 cells showed no significant time dependency up to 24 h postirradiation, while out-of-field survival decreased significantly during the first 6 h postirradiation (P < 0.05). While in-field responses were oxygen dependent, out-of-field effects were observed to be independent of oxygen, with similar or greater cell killing under hypoxic conditions. This study provides further understanding of intercellular signaling under hypoxic conditions and highlights the need for further refinement of established radiobiological models for future applications in advanced radiotherapies.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29019742     DOI: 10.1667/RR14836.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  5 in total

1.  Intensity Modulated Radiation Fields Induce Protective Effects and Reduce Importance of Dose-Rate Effects.

Authors:  Yusuke Matsuya; Stephen J McMahon; Mihaela Ghita; Yuji Yoshii; Tatsuhiko Sato; Hiroyuki Date; Kevin M Prise
Journal:  Sci Rep       Date:  2019-07-01       Impact factor: 4.379

2.  The Roles of HIF-1α in Radiosensitivity and Radiation-Induced Bystander Effects Under Hypoxia.

Authors:  Jianghong Zhang; Yuhong Zhang; Fang Mo; Gaurang Patel; Karl Butterworth; Chunlin Shao; Kevin M Prise
Journal:  Front Cell Dev Biol       Date:  2021-03-25

3.  No Intercellular Regulation of the Cell Cycle among Human Cervical Carcinoma HeLa Cells Expressing Fluorescent Ubiquitination-Based Cell-Cycle Indicators in Modulated Radiation Fields.

Authors:  Hisanori Fukunaga; Kiichi Kaminaga; Eri Hirose; Ritsuko Watanabe; Noriko Usami; Kevin M Prise; Akinari Yokoya
Journal:  Int J Mol Sci       Date:  2021-11-26       Impact factor: 5.923

4.  Development of a portable hypoxia chamber for ultra-high dose rate laser-driven proton radiobiology applications.

Authors:  Pankaj Chaudhary; Deborah C Gwynne; Boris Odlozilik; Aaron McMurray; Giuliana Milluzzo; Carla Maiorino; Domenico Doria; Hamad Ahmed; Lorenzo Romagnani; Aaron Alejo; Hersimerjit Padda; James Green; David Carroll; Nicola Booth; Paul McKenna; Satyabrata Kar; Giada Petringa; Roberto Catalano; Francesco P Cammarata; Giuseppe A P Cirrone; Stephen J McMahon; Kevin M Prise; Marco Borghesi
Journal:  Radiat Oncol       Date:  2022-04-15       Impact factor: 4.309

5.  Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer.

Authors:  Becky A S Bibby; Niluja Thiruthaneeswaran; Lingjian Yang; Ronnie R Pereira; Elisabet More; Darragh G McArt; Paul O'Reilly; Robert G Bristow; Kaye J Williams; Ananya Choudhury; Catharine M L West
Journal:  BMC Urol       Date:  2021-07-01       Impact factor: 2.264

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.